Bemnifosbuvir for COVID-19: real-time meta analysis of 4 studies

Meta analysis using the most serious outcome reported shows 32% [-74‑73%] lower risk, without reaching statistical significance. Results are better for peer-reviewed studies. Currently all studies are RCTs.

2 studies (both from the same team/sponsor) show significant benefit.

Control Bemnifosbuvir

Currently there is limited data, with only 11 control events for the most serious outcome in trials to date. All studies to date are from the same group.

No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Other treatments are more effective. All data and sources to reproduce this analysis are in the appendix.